Nurix Therapeutics, INC. (NRIX) — 10-Q Filings

10-Q Filings (7)

• Nurix Therapeutics Files Q1 2026 10-Q Report — Apr 8, 2026 Risk: low
  Nurix Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ending February 28, 2026. The filing includes financial statements and disclosur
• Nurix's Losses Widen to $186M Amid Soaring R&D Costs — Oct 9, 2025 Risk: high
  Nurix Therapeutics, Inc. reported a significant increase in net loss for the nine months ended August 31, 2025, reaching $(186.2) million, up from $(135.0) mill
• Nurix Collaboration Revenue Jumps 38% in Q2 — Jul 9, 2025 Risk: medium
  Nurix Therapeutics, Inc. reported collaboration revenue of $10.9 million for the three months ended May 31, 2025, a significant increase from $7.9 million for t
• Nurix Therapeutics Files Q1 2025 10-Q — Apr 8, 2025 Risk: medium
  Nurix Therapeutics, Inc. filed a 10-Q for the period ending February 28, 2025. The filing covers the first quarter of their fiscal year. Key financial data and
• Nurix Therapeutics Q3 Revenue Rises — Oct 11, 2024 Risk: medium
  Nurix Therapeutics, Inc. filed its 10-Q for the period ending August 31, 2024. The company reported collaboration revenue of $12.5 million for the three months
• Nurix Therapeutics Q2 Revenue Declines — Jul 11, 2024 Risk: medium
  Nurix Therapeutics, Inc. filed its 10-Q for the period ending May 31, 2024. The company reported collaboration revenue of $10.1 million for the three months end
• Nurix Therapeutics, Inc. Files 10-Q for Period Ending February 29, 2024 — Apr 10, 2024 Risk: low
  Nurix Therapeutics, Inc. (NRIX) filed a Quarterly Report (10-Q) with the SEC on April 10, 2024. Nurix Therapeutics, Inc. filed a 10-Q for the period ending Febr

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX